Novel Patent Targets The Most Common Sleep Complaint Chronic Insomnia: related news

Novel Patent Targets The Most Common Sleep Complaint: Chronic Insomnia

Consolidated Research of Richmond, Inc. (CRI) announces the awarding of United States Patent 7,654,948 - which is a novel, drug-free system for treating people suffering from the most common sleep complaint: Chronic Insomnia.

CardinalCommerce Corporation Reports Patent Grant by the United States Patent and Trademark Office

MENTOR, Ohio, Feb. 11, 2010 (GLOBE NEWSWIRE) -- CardinalCommerce, the worldwide leading enabler of payment brands, announced today that it has been granted its fourth patent from the United States Patent and Trademark Office. U.S. Patent No. 7,624,039 B2 was issued to CardinalCommerce on November 24, 2009. This latest patent, titled Affinity Shopping Portal, complements the company's current patent holdings, as well as its patent applications. Cardinal's IP portfolio includes three additional United States, three European, and two South African patents: US Patents: Patent No. US 7,051,002 Patent No. US 7,140,036 Patent No. US 7,606,771 Patent No. EP 1 221 146 B1 (UK, European Patents: CH) Patent No. DE 600 15 587.0-08 South African Patents: Patent No.

Patent Law Institute (4th Annual)

PLI’s 4th Annual Patent Law Institute is designed to cover the practice impact of recent developments on all three sub-groups in the patent law community: patent prosecutors, patent litigators, and patent strategic & transactional lawyers. The two-day schedule includes 6 one-hour plenary sessions of broad interest to patent lawyers and a separate breakout track for prosecution, litigation and strategic & transactional practices. Each track features 6 one-hour breakout sessions focused on each of the 3 patent practice sub-groups. In just two days, you will learn the important developments and best practices in each area. And earn Ethics credit, too! You can design the Institute schedule that best meets your individual practice needs. Do not miss this unique opportunity to sharpen your practice skills and to network with federal judges, U

Seaside Therapeutics Announces Issuance Of Key Patent For Treatment Of Autism Spectrum Disorders

Seaside Therapeutics LLC announced the issuance of U.S. patent 7,648,993 B2 ('993 patent), which covers methods of treating autism with group 1 antagonists of the metabotropic glutamate receptor (mGluR) pathway. An earlier related patent, U.S. patent 6,890,931 B2 ('931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway. Related patents have also issued in Europe (EP 1 392 363 B1) and have been allowed in Canada. Together, these patents form the foundation of Seaside's intellectual property estate. The method of use claims in these patents reflect critical observations of the mGluR pathway and its implications in the causation of Fragile X Syndrome, autism and other disorders of brain development.

Government Expands Scope of Accelerated Patent Examination

The Taiwan Intellectual Property Office (TIPO) has expanded the scope of application of the Accelerated Examination Program (AEP) this year in order to speed up the patent examination procedure. An applicant may request accelerated examination if an examination opinion has been obtained from a patent office in the United States or Japan or from the European Patent Office, and if proof of business necessity is provided. TIPO points out that the concept of patent protection is widely accepted today, resulting in a great increase in patent applications. To speed up examination of the constantly growing number of cases, TIPO brought in the spirit of the international Patent Prosecution Highway (PPH) system in 2009, permitting application for accelerated examination for patent applications in a foreign country that have received approval for s

Patent Prosecution in Regional/National Patent Offices

Now I will review some basic differences between U.S. patent prosecution procedures and international procedures. In the interest of brevity, I will review prosecution in the European Patent Office (EPO) and in the Japanese Patent Office. These two systems, along with the U.S. patent system, are generally considered the most developed.

US patent for Avanir Pharma's low-dose quinidine formulations of Zeniva

Avanir Pharmaceuticals, Inc announced that the United States Patent and Trademark Office (US PTO) has issued the company a new patent for its lead drug candidate Zenvia (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. US patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide Avanir with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

Patent Infringement Complaint Filed By Lifetime Products Against Three Chinese Companies

Patent Infringement Complaint Filed By Lifetime Products Against Three Chinese CompaniesA leader in the blow-molded folding table and chair market, Lifetime Products, has filed a patent infringement complaint with the Shanghai No. 1 Intermediate People's Court for the People's

US Patent Office Decides That One Click Really Is Patentable

Ladies and gentlemen, we now have confirmation that the USPTO is a joke. After years of back and forth, it has decided, once again, that Amazon's one-click patent is perfectly valid. This, despite tons of prior art, and basic common sense. We were just wondering what was taking so long for the USPTO to reject the patent. But, of course, it seemed like the USPTO was willing to go out of its way to help keep this patent around. Of course, as some are pointing out, the end result of this patent surviving is that it may be used as example number one for patent reform.

Chicago gets taste of Patent Bar review

PLI has a built a tradition of serving patent lawyers the most reliable review course. PLI's Patent Bar Review Course begins its 2010 rounds and will land in Chicago, March 17 to 21. John M. White, director of patent professional development at PLI, will lead patent bar candidates through the intricacies -- and around the traps -- of the Patent Bar Exam.

Smith a common name. Shock ? Kate Ellis Twitter hack

Stating the obvious. Dear today’s edition of the Cobram Courier. According to Wikipedia, the surname “Smith� is the most common surname in the USA, England, Scotland, Australia and the second most common surname in Canada. There’s a fairly good chance it will be the most common surname in Cobram, Victoria, population approximately 5300.

ALDA Receives Australian Patent for T36(R) Disinfectant

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("ALDA") is pleased to announce that Australian Patent Number 2007237333 has been issued by the Australian Patent Office. This new patent is a divisional of Australian Patent Number 2002322916 that was issued on January 10, 2008 and provides further protection for ALDA's T36® formulation until August 20, 2022. The divisional patent includes claims to additional aspects of the T36® formulation, including the use of T36® as a component of a personal lubricant, in a method of preventing or reducing the transmission of sexually transmitted diseases including Herpes, Chlamydia and HIV and as a sanitizer or cleanser in the form of creams, ointments and wipes. The divisional patent also includes claims to methods of producing T36®.

ALDA Receives Australian Patent for T36(R) Disinfectant

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("ALDA") is pleased to announce that Australian Patent Number 2007237333 has been issued by the Australian Patent Office. This new patent is a divisional of Australian Patent Number 2002322916 that was issued on January 10, 2008 and provides further protection for ALDA's T36(R) formulation until August 20, 2022. The divisional patent includes claims to additional aspects of the T36(R) formulation, including the use of T36(R) as a component of a personal lubricant, in a method of preventing or reducing the transmission of sexually transmitted diseases including Herpes, Chlamydia and HIV and as a sanitizer or cleanser in the form of creams, ointments and wipes. The divisional patent also includes claims to methods of producing T36(R).

Medical News: QR Pharma Receives US Patent 7,625,942 To Treat Down Syndrome

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-β precursor protein (APP) and thereby treat dementia and Alzheimer's disease (AD).

QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome

RADNOR, Pa.(BUSINESS WIRE) QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it was issued U.S. Patent No. 7,625,942, a "Method of Treating Down Syndrome" by the U.S. Patent and Trademark Office. The '942 patent covers use of Posiphen and analogs to treat cognitive impairments associated with Down Syndrome (DS). This patent valuably expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid- precursor protein (APP) and thereby treat dementia and Alzheimer's disease (AD).

AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent

today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia(TM) (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

Media briefs: Smith a common name. Shock ? Kate Ellis Twitter hack ? China vs. Google ?

Stating the obvious. Dear today’s edition of the Cobram Courier. According to Wikipedia, the surname “Smith� is the most common surname in the USA, England, Scotland, Australia and the second most common surname in Canada. There’s a fairly good chance it will be the most common surname in Cobram, Victoria, population approximately 5300.

Transcept Pharmaceuticals Granted First U.S. Patent Covering Intermezzo Formulation

Transcept Pharmaceuticals, Inc. today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent Application Serial No. 11/060,641, on December 14, 2009. The newly issued patent, U.S. Patent No. 7,658,945, titled "Compositions for Delivering Hypnotic Agents Across the Oral Mucosa and Methods of Use Thereof," will expire no earlier than February 2025.

ZTE tops China?s patent application ranking list

ZTE Corporation (“ZTE� - H share stock code: 00763.HK / A share stock code: 000063.SZ), a leading global provider of telecommunications equipment and network has reported that the Patent Protection Association of China (PPAC) recently released patent application rankings for 2009 with ZTE, Huawei and Hongfujin claiming the top three spots on the ranking list. With 5,719 patent applications, ZTE widened its lead over its competitors, claiming the top spot for the first time. The number of patent applications filed by ZTE in 2009 was up over 20% compared to the number filed in 2008. Meanwhile, ZTE also saw its overseas patent applications increase over 200%, hitting 1,164, achieving the fastest growth of patent applications in the world.

Transcept Pharmaceuticals Granted First U.S. Patent Covering Intermezzo(R) Formulation

POINT RICHMOND, Calif., Feb. 9 /PRNewswire-FirstCall/ --Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent Application Serial No. 11/060,641, on December 14, 2009. The newly issued patent, U.S. Patent No. 7,658,945, titled "Compositions for Delivering Hypnotic Agents Across the Oral Mucosa and Methods of Use Thereof," will expire no earlier than February 2025.

AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent

ALISO VIEJO, Calif.(BUSINESS WIRE) AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia? (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

U.S. Patent And Trademark Office Issues AVANIR Pharma New Patent For Zenvia - Quick Facts

(RTTNews) - AVANIR Pharma Inc. (AVNR: News ) announced that the U.S. Patent and Trademark Office has issued the company a new patent for its lead drug candidate Zenvia, extending the period of patent protection in the United States into late 2025. The patent, titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010.

US Patent Office Grants WordLogic 2nd Patent; 39 Claims Cover Touch Screen Digital Keyboards

VANCOUVER, March 17 /PRNewswire/ -- WordLogic Corporation, a leading developer of multiplatform predictive text software, has been granted its second patent by the U.S. Patent and Trademark Office (USPTO). The USPTO issued Patent No. 7681124 titled "Data Entry for Personal Computing Devices" on March 16, 2010. This patent consists of a total of 39 claims pertaining primarily for touch screen digital keyboards.

Search took 0.90 seconds.